Apellis Pharmaceuticals Earnings Estimate
| APLS Stock | USD 27.35 0.40 1.44% |
Apellis Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Apellis Pharmaceuticals' earnings estimates, investors can diagnose different trends across Apellis Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Apellis Pharmaceuticals' Gross Profit is comparatively stable compared to the past year. Gross Profit Margin is likely to gain to 0.98 in 2025, whereas Pretax Profit Margin is likely to drop (0.26) in 2025. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Apellis Pharmaceuticals Earnings Estimation Breakdown
The calculation of Apellis Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Apellis Pharmaceuticals is estimated to be -0.099775 with the future projection ranging from a low of -0.5725 to a high of 0.16. Please be aware that this consensus of annual earnings estimates for Apellis Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.57 Lowest | Expected EPS | 0.16 Highest |
Apellis Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Apellis Pharmaceuticals' value are higher than the current market price of the Apellis Pharmaceuticals stock. In this case, investors may conclude that Apellis Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Apellis Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 21 | 75.43% | 0.0 | -0.099775 | -1.83 |
Apellis Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Apellis Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Apellis Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Apellis Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Apellis Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Apellis Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Apellis Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Apellis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-07-31 | 2025-06-30 | -0.48 | -0.33 | 0.15 | 31 | ||
2025-05-05 | 2025-03-31 | -0.54 | -0.74 | -0.2 | 37 | ||
2025-02-25 | 2024-12-31 | -0.4019 | -0.29 | 0.1119 | 27 | ||
2024-11-05 | 2024-09-30 | -0.3 | -0.4624 | -0.1624 | 54 | ||
2024-08-01 | 2024-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2024-02-27 | 2023-12-31 | -0.69 | -0.73 | -0.04 | 5 | ||
2023-11-01 | 2023-09-30 | -0.86 | -1.17 | -0.31 | 36 | ||
2023-07-31 | 2023-06-30 | -1.32 | -1.02 | 0.3 | 22 | ||
2023-05-04 | 2023-03-31 | -1.46 | -1.56 | -0.1 | 6 | ||
2023-02-21 | 2022-12-31 | -1.57 | -1.5 | 0.07 | 4 | ||
2022-11-07 | 2022-09-30 | -1.45 | -1.75 | -0.3 | 20 | ||
2022-08-08 | 2022-06-30 | -1.36 | -1.46 | -0.1 | 7 | ||
2022-05-04 | 2022-03-31 | -1.32 | -1.42 | -0.1 | 7 | ||
2022-02-28 | 2021-12-31 | -1.54 | -1.61 | -0.07 | 4 | ||
2021-11-08 | 2021-09-30 | -1.7 | -2.28 | -0.58 | 34 | ||
2021-08-09 | 2021-06-30 | -1.69 | -2.72 | -1.03 | 60 | ||
2021-04-28 | 2021-03-31 | -1.62 | -2.32 | -0.7 | 43 | ||
2021-02-25 | 2020-12-31 | -0.75 | 0.93 | 1.68 | 224 | ||
2020-11-02 | 2020-09-30 | -1.58 | -1.79 | -0.21 | 13 | ||
2020-07-30 | 2020-06-30 | -1.34 | -1.57 | -0.23 | 17 | ||
2020-04-29 | 2020-03-31 | -1.38 | -2.29 | -0.91 | 65 | ||
2020-02-27 | 2019-12-31 | -1.14 | -1.77 | -0.63 | 55 | ||
2019-11-05 | 2019-09-30 | -1.01 | -1.1 | -0.09 | 8 | ||
2019-07-31 | 2019-06-30 | -0.77 | -1.12 | -0.35 | 45 | ||
2019-05-07 | 2019-03-31 | -0.67 | -0.87 | -0.2 | 29 | ||
2019-02-26 | 2018-12-31 | -0.7 | -0.65 | 0.05 | 7 | ||
2018-11-13 | 2018-09-30 | -0.69 | -0.64 | 0.05 | 7 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2017-12-20 | 2017-09-30 | -0.87 | -1.37 | -0.5 | 57 | ||
2017-08-30 | 2017-06-30 | 0 | -1.26 | -1.26 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -1.07 | -1.07 | 0 |
About Apellis Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Apellis Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Apellis Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Apellis Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -3 B | -2.9 B | |
| Earnings Yield | (0.05) | (0.05) | |
| Price Earnings Ratio | (19.98) | (18.98) | |
| Price Earnings To Growth Ratio | 0.31 | 0.30 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.